Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.58) by 34.48 percent. This is a 29.09 percent increase over losses of $(1.10) per share from the same period last year. The company reported quarterly sales of $68.728 million which beat the analyst consensus estimate of $63.968 million by 7.44 percent. This is a 794.90 percent increase over sales of $7.680 million the same period last year.